Caribou Biosciences to Present Preclinical Data on CB-010 for Lupus at ACR Convergence 2024
Caribou Biosciences, Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that an abstract for a poster presentation at the American College of Rheumatology (ACR) Convergence 2024 has been accepted. The event is scheduled for November 14-19, 2024, in Washington, DC. The presentation will focus on preclinical data and key elements of the clinical trial design that supported the investigational new drug (IND) clearance for CB-010, aimed at evaluating its efficacy in the GALLOP Phase 1 clinical trial for patients with lupus nephritis (LN) and extrarenal lupus (ERL).
Details of the Poster Presentation:
- Title: Preclinical Analysis of CB-010, an Allogeneic anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, for the Treatment of Patients with Refractory Systemic Lupus Erythematosus (SLE)
- Presenter: Elizabeth Garner, PhD, executive director of T cell therapeutics and translational sciences laboratory, Caribou Biosciences
- Date and Time: Saturday, November 16, 2024, 10:30 am-12:30 pm EST
- Session: B cell biology & targets in autoimmune & inflammatory disease poster
- Location: Walter E. Washington Convention Center, Washington, DC
- Abstract Number: 0018
The 2024 ACR Convergence abstracts will be published on www.acrabstracts.org, and the poster presentation will be available on Caribou’s Scientific Publications webpage starting Thursday, November 14, 2024, at 10:00 am EST.
About CB-010: CB-010 is Caribou’s leading clinical-stage product candidate from its allogeneic CAR-T cell therapy platform. It is currently being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1 clinical trial and will be assessed in patients with lupus nephritis (LN) and extrarenal lupus (ERL) in the GALLOP Phase 1 clinical trial. CB-010 is notable for being the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to enhance CAR-T cell activity by preventing premature CAR-T cell exhaustion. The FDA has granted CB-010 Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations for B-NHL, along with Fast Track designations for both B-NHL and refractory systemic lupus erythematosus (SLE).
About Caribou’s Novel Next-Generation CRISPR Platform: Caribou Biosciences leverages CRISPR genome editing technology to develop transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision in developing cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.